Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Pulls Absorb Stent Off The Market, Citing Low Sales

Executive Summary

Abbott is giving up on selling its first-generation biosorbable coronary stent, which failed to match the performance of contemporary metallic drug-eluting stents in clinical trials. The company says it will continue working on the next-generation biosorbable stents and continue the ongoing trials of Absorb GT1 BVS.

You may also be interested in...



Start-Up Spotlight: Elixir Works To 'Uncage' The Coronary After Intervention

The company is sponsoring INFINITY SWEDEHEART, a randomized trial of its DynamX Bioadaptor, a unique metallic coronary artery implant that adapts to vessel physiology.

Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps

The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.

TCT 2018: New ABSORB Trial Data Fails To Impress

Abbott's defunct Absorb BVS stent's efficacy is noninferior to that of the Xience metallic everolimus-eluting stent, new data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego show. But the risk of thrombotic events was still higher with Absorb. This prompted a discussion among panelists whether bioresorbable stents should still be investigated, given the availability of newer-generation drug-eluting stents, which have shown to be safer.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT121467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel